{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020871","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.070168+00:00","generated_at":"2026-06-15T03:59:56.183835+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kintara reports Q3 FY2023 net loss of $3.3M; cash at $3.0M; GBM data expected by year-end","bullets":["Net loss $3.3M ($1.94 per share) vs. $5.4M ($5.45) in prior-year quarter; R&D spending down 42%.","Cash and cash equivalents $3.0M as of March 31, 2023; working capital $3.2M.","Top-line data from registrational GBM AGILE study for VAL-083 expected before end of calendar 2023.","Case study data from expanded access program for VAL-083 presented at AACR; REM-001 program paused to conserve cash."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020871","json":"https://secwatch.observer/filing/0000950170-23-020871.json","markdown":"https://secwatch.observer/filing/0000950170-23-020871.md","text":"https://secwatch.observer/filing/0000950170-23-020871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023020871/0000950170-23-020871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023020871/ktra-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:59:56.183835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6fc5dcaf8a451ad4cfea1331eda7548211a710b","claim":"TuHURA Biosciences, Inc./NV reported fiscal third quarter ended March 31, 2023 results: net income net loss of approximately $3.3 million, EPS $1.94 per share.","evidence_excerpt":"For the three months ended March 31, 2023, Kintara reported a net loss of approximately $3.3 million, or $1.94 per share, compared to a net loss of approximately $5.4 million, or $5.45 per share, for the three months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023020871/0000950170-23-020871-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal third quarter ended March 31, 2023"},{"label":"Net income","value":"net loss of approximately $3.3 million"},{"label":"EPS","value":"$1.94 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b593082271a067eb42e4396b16cb0cde52ed3242","claim":"TuHURA Biosciences, Inc./NV reported the nine months ended March 31, 2023 results: net income net loss of approximately $11.3 million, EPS $7.32 per share.","evidence_excerpt":"For the nine months ended March 31, 2023, Kintara reported a net loss of approximately $11.3 million, or $7.32 per share, compared to a net loss of approximately $17.2 million, or $22.39 per share, for the nine months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023020871/0000950170-23-020871-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended March 31, 2023"},{"label":"Net income","value":"net loss of approximately $11.3 million"},{"label":"EPS","value":"$7.32 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}